What’s more, BVT.2733 treatment for four weeks also caused a marked increase in the expression of adipokines including adiponectin and vaspin in adipose tissue in vivo and we also found that BVT.2733 administration normalized the expression of vaspin (Fig. S1C) and resistin (Fig. S1D) in PA-treated adipocyte in vitro. Thus, our findings further confirmed that BVT.2733 could be regarded as an effective agent that ameliorates obesity and metabolic syndrome. The gene discussed is ADIPOQ; the disease is obesity disorder.